BCT 200

Drug Profile

BCT 200

Alternative Names: BCT-200

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Bio-Cancer Treatment International
  • Class Polyethylene glycols; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Graft-versus-host disease; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 15 Jan 2016 Preclinical trials in Graft-versus-host disease in Hong Kong (IV) prior to January 2016
  • 15 Jan 2016 Preclinical trials in Rheumatoid arthritis in Hong Kong (IV) prior to January 2016
  • 15 Jan 2016 Preclinical trials in Multiple sclerosis in Hong Kong (IV) prior to January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top